New from BrainScope Company Inc is the Ahead 300, designed to provide a rapid assessment of a patient’s mild head injury, including concussion, at the point of care for up to 3 days following the injury.

The Ahead 300 addresses two key questions, according to the company: whether the patient has a traumatic structural brain injury that would be visible on a CT scan, or is there evidence of something functionally abnormal with the brain after head injury, which could be concussion?

Developed in partnership with the US Department of Defense, the Ahead 300 features a disposable sensor headset and a handheld technology, upon which four objective tests and 16 standard concussion assessment tools can be customized into a configurable panel.

“The Ahead 300 is the first-to-market medical technology capable of providing objective, easily accessible and multimodal information in a panel format for up to 3 days following injury. As the first line of assessment, the Ahead 300 can have significant impact on helping the clinician make their diagnosis for proper patient disposition,” says Michael Singer, CEO of BrainScope, in the release.

[Source(s): BrainScope, BusinessWire]